非小细胞肺癌论文：非小细胞肺癌分子标志物和其临床相关性研究.docVIP

非小细胞肺癌论文：非小细胞肺癌分子标志物及其临床相关性研究 【中文摘要】背景和:肺癌是世界第一大恶性肿瘤,其发病率及死亡率居高不下,寻找肺癌早期标志物以及肺癌的预后标志物,将有助于肺癌的早期诊断和辅助指导肺癌的治疗。方法:本研究收集具有完整的临床和病理资料的非小细胞肺癌(NSCLC)标本196例,其中鳞癌88例,腺癌108例。应用组织芯片联合免疫组织化学技术,对20个蛋白的表达情况进行检测,分析其与临床病理参数的相关性。结果:对所测20个候选蛋白的分析发现,与癌旁形态学正常的组织相比,癌组织中uPA、ET-1、p53、ki67和EGFR显示较高频率的异常表达。其中,uPA阴性/弱、中度和高表达在鳞癌中的比例分别为13.3%、62.7%和24.0%,在腺癌中各为13.1%、52.4%和34.5%。ET-1在鳞癌中阴性/弱、中度和高表达分别为2.7%、41.9%和55.4%,在腺癌中各为10.6%、31.8%和57.6%。uPA高表达或与ET-1同时高表达的腺癌患者具有较长的术后生存时间(P = 0.012和0.016)。p53、ki67和EGFR在肺鳞癌强阳性率分别为59.3%、65.4%和67.9%,在肺腺癌强阳性率各为60.4%、44.0%和54.9%,而在癌旁形态学正常的组织表达率仅为14.0%、7.0%和12.2%。结论:uPA和ET-1蛋白联合很有可能作为一个有应用价值的非小细胞肺癌预后因子。p53、ki67、EGFR三种蛋白在肺癌组织高表达,而在手术切端组织不表达或仅微弱表达,很有可能作为肺癌诊断的重要分子标志。 【英文摘要】BACKGROUND : Lung cancer is the leading cause of cancer death in the world. The morbidity and mortality rates remain highest in all cancers, so finding predictable molecular markers for lung cancer will help to reduce the incidence and to improve accuracy rate of clinical diagnosis and individualized treatment of lung cancer.METHODS: We collected 196 cases of Non-small cell lung cancer (NSCLC) with clinical and pathological data. Expression of 20 candidate proteins was detected by using the techniques of tissue microarrays and immunohistochemistry (TMA-IHC). The correlations between the alteration of the proteins and clinicopathological parameters were analyzed.RESULTS: In the tested 20 proteins, uPA、ET-1、p53、ki67 and EGFR presented higher frequencies of abnormal expression in cancer tissues. Negative/weak, moderate and high expression of uPA were observed in 12.3%, 64.4% and 23.3% of squamous cell carcinomas, in 12.2%, 53.7% and 34.1% of adenocarcinomas, and in 12.3%, 58.7% and 29.0% of all cases. ET-1 presented negative/weak, moderate and high expression in 2.7%, 42.5% and 54.8%of squamous cell carcinomas, in 11.0%, 30.5% and 58.5% of adenocarcinomas, and in 7.1%, 36.1% and 56.8%of all cases. Adenocarcinoma patients with high expression of uPA or with high expression of both ET-1 and uPA with had